University College London at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
University College London takes part in 8 sessions at ESMO 2026 in Madrid. Its program centres on cancer biology and translational research, from cell plasticity and tumour evolution to tracking metastatic growth in lung cancer. Other sessions cover gene expression-based risk grouping in very high-risk prostate cancer, adjuvant durvalumab in resected kidney cancer and drug therapy for locally advanced liver cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
University College London London, United Kingdom | |
Public research university in London, England, with a medical school and a cancer institute. | Chair Fri Oct 23 13:30–15:00 Key biological concepts and their clinical implication Biomarkers & precision oncology Talk Fri Oct 23 14:10–14:30 Cancer cell plasticity and cancer evolution Biomarkers & precision oncology Abstract Sat Oct 24 11:10–11:20 Chair Sat Oct 24 14:45–16:00 Management of locally advanced HCC Gastrointestinal cancers Talk Sat Oct 24 14:50–15:05 View of the medical oncologist: Integration of systemic therapies with locoregional therapy Gastrointestinal cancers Talk Sun Oct 25 11:15–11:30 Advanced/metastatic prostate cancer: Discussion Breast cancerGenitourinary cancers Chair Sun Oct 25 14:45–16:15 Abstract Sun Oct 25 14:50–14:55 Abstract Sun Oct 25 15:05–15:15 Abstract Sun Oct 25 15:57–16:07 Chair Mon Oct 26 12:15–12:45 Abstract Mon Oct 26 15:05–15:17 Invited Discussant 4240O, 4241O and 4242O Biomarkers & precision oncology |
Instantly find 20 buyers from University College London
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction